Leffel Discusses Third-Party Litigation Funding in Wisconsin Amid New Transparency Law
April 10, 2018
Law.com
Partner Michael Leffel was quoted in a Law.com article, “What’s Next: A Groundbreaking Lit Funding Transparency Law, and More Pressure on Big Tech Over Privacy,” about the frequency of third-party litigation funding in Wisconsin amid the passing of Assembly Bill 773, which makes Wisconsin the first U.S. state to require the disclosure of third-party litigation funding in civil actions filed in state court.
“[Third-party litigation funding] is something that does not appear to be used that often in Wisconsin at this time,” said Leffel. Although there hasn’t been significant controversy over litigation funding in Wisconsin, Law.com reports the new law is the country’s first step toward uniform transparency rules on litigation funding contracts.
Subscription required.
“[Third-party litigation funding] is something that does not appear to be used that often in Wisconsin at this time,” said Leffel. Although there hasn’t been significant controversy over litigation funding in Wisconsin, Law.com reports the new law is the country’s first step toward uniform transparency rules on litigation funding contracts.
Subscription required.
People
Related News
June 10, 2025
In the News
Lynn Gandhi Sheds Light on Supreme Court Tax Ruling
Foley partner Lynn Gandhi commented in the Bloomberg Tax article "High Court’s Catholic Charities Case to Go Beyond Unemployment," sharing insight on the implications of the recent Supreme Court ruling in a tax case.
June 10, 2025
In the News
James McFall Joins Iconic Athletes and Leaders in Launch of Stanford Football Alumni United
Foley & Lardner LLP is proud to announce that partner James Carlos McFall is a founding member of Stanford Football Alumni United (SFAU), a newly formed coalition of former players and leaders committed to supporting Stanford Football’s continued growth and national competitiveness.
June 6, 2025
In the News
David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration's drug shortage list in the BioSpace article, "Post-Chevron Legal Battles: Three Key Cases to Watch."